Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Phase 3ASC30GLP-1/GIP/Amylin fixed-dose combinationPositive

AI Analysis

Summary

Ascletis has initiated a global Phase III program for ASC30, an oral GLP-1 small molecule, enrolling approximately 4,600 participants with obesity or overweight across the U.S., Europe, and Canada. The company also announced positive preclinical data for its first-in-class oral GLP-1/GIP/Amylin fixed-dose combination.

Clinical Trial Data

Phase

Phase III

Patients

4,600

Outcome Details

Global Phase III program initiated for ASC30 with positive preclinical data for GLP-1/GIP/Amylin combination

Importance:7/10

Sentiment:

0.70

Phase 3 initiationGLP-1 agonistobesityoral small moleculepreclinical datamulti-regional trial

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Biotech on August 3, 2026 10:55 AM

Read Original